24 trends tracked about this subject — the full history, oldest to newest below.
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
A major review of nearly 200 preclinical studies and major clinical trials finds that GLP-1 obesity drugs may protect the brain, but randomized trials have not shown a clear cognitive benefit.
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
Obesity drugs face a major pivot as clinical trials investigate their potential to treat addiction, depression, and criminal behavior.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Recent analysis reveals semaglutide improves heart health and benefits frail patients independently of weight loss.
Recent scientific research indicates that a new RNA therapy could potentially prevent lean muscle loss during GLP-1 weight loss treatments.
Recent coverage examines rapid weight regain after discontinuing GLP-1 medications like Ozempic, semaglutide, and tirzepatide.
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
Growing concerns emerge over the 'Ozempidemic' as users report intense cravings and safety risks associated with GLP-1 weight-loss medications.
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.
New research indicates that semaglutide treatment administered late in life can slow the aging process and extend the lifespan of female mice.
Recent studies reveal that the GLP-1 receptor agonist semaglutide extends lifespan and slows physiological aging in animal models.
Emerging research suggests GLP-1 medications, primarily known for weight loss, may offer an unexpected therapeutic benefit in treating substance addictions.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
Researchers screening 6,000 existing medications have identified potential anti-aging properties in common drugs, including GLP-1 weight loss treatments.
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
New research indicates that GLP-1 obesity medications may provide unexpected benefits for male fertility by increasing testosterone and sperm quality.
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss